Haleon PLC
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Brian James McNamara
- Full Time Employees
- 24,535
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- The Heights Weybridge SU United Kingdom KT13 0NY
- IPO Date
- Jul 18, 2022
- Website
- haleon.com
- Similar Companies
- Business
- Haleon plc is a leading global consumer healthcare company that develops and markets a broad portfolio of over-the-counter products across six key categories: oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health, and therapeutic skin health and other; its power brands include Sensodyne and parodontax toothpastes, Polident denture care, Centrum multivitamins, Emergen-C vitamin C supplements, Caltrate calcium supplements, Panadol and Advil analgesics, Voltaren topical pain relief, Otrivin nasal decongestants, Theraflu cold and flu remedies, ENO and Tums antacids, and Benefiber fiber supplements. The company operates in over 170 markets worldwide through three geographical segments—North America, Europe, Middle East, Africa and Latin America (EMEA & LatAm), and Asia Pacific (APAC)—with manufacturing sites and sales focused on consumers seeking everyday health solutions recommended by health professionals. Founded from heritage dating to 1715 and spun off from GlaxoSmithKline as a standalone entity in July 2022, Haleon plc maintains its headquarters in Weybridge, UK. In recent developments, Haleon completed the acquisition of the remaining 12% equity interest in its China joint venture Tianjin TSKF Pharmaceutical Co. Ltd in June 2025 for approximately £0.2 billion, making it a wholly owned subsidiary that manufactures and distributes brands such as Fenbid, Voltaren and Bactroban and represents about 40% of its China revenues; the company also divested ChapStick for $430 million, completed a £500 million share buyback programme in 2025, and launched innovations including new products for Sensodyne, parodontax, Centrum, Emergen-C and Caltrate amid strong organic revenue growth in oral health and VMS categories.
Company News
UBS says early flu pick-up could lift 2027 earnings at Reckitt and Haleon
Haleon Launches ‘Haleon Health House,' a One-Day Interactive Wellness Pop-Up in Toronto
Only Excedrin Brings Digital Pet Nostalgia Back with a Headache You Can't Ignore
Goldman Sachs Top European Stock Picks Have a Hidden Perk for Income Investors
Unilever on JP Morgan positive watch as Haleon faces caution
LCUT vs. HLN: Which Stock Is the Better Value Option?
Advil-maker Haleon boosts US sales by targeting consumers on weight-loss drugs
LCUT or HLN: Which Is the Better Value Stock Right Now?
Haleon secures better shelf space at Walmart, Target in bid to boost market share
Comparing Haleon (NYSE:HLN) & Procter & Gamble (NYSE:PG)
LCUT vs. HLN: Which Stock Is the Better Value Option?
Jefferies raises Haleon price target to 410p on margin strength
Haleon plc: Announces Pricing Terms, Expiration and Results of its Cash Tender Offer for outstanding 2027 Notes
Haleon plc: Cash tender offer for outstanding 2027 3.375% Fixed Rate Notes
Haleon plc (LON:HLN) Receives Average Recommendation of “Hold” from Analysts
Haleon plc (HLN) Q2 2026 Earnings Call Prepared Remarks Transcript
ACCO vs. HLN: Which Stock Is the Better Value Option?
Haleon slides as quality of growth questioned
Haleon plc (HLN) Q2 2026 Earnings Call Transcript
Bank of New York Mellon Corp Has $25.99 Million Stock Position in Haleon PLC Sponsored ADR $HLN